NCT06840886 2026-04-22
A Study of PHST001 in Advanced Solid Tumors
Pheast Therapeutics
Phase 1 Recruiting
Clinical Trials
14 trialsNCT07545460 2026-04-22
A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT06828354 2026-04-20
A Study of SHR-A1811 in Subjects With Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Recruiting
NCT06994195 2026-04-20
A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT06459180 2026-04-17
TroFuse-020
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07213804 2026-04-17
FRAmework-01
Eli Lilly and Company
Phase 3 Recruiting
NCT07214779 2026-04-16
MAESTRA 2
Incyte Corporation
Phase 3 Recruiting
NCT04739800 2026-04-13
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT07418749 2026-04-06
A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Recruiting
NCT06930755 2026-03-31
Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer
Nerviano Medical Sciences
Phase 1 Recruiting
NCT07286266 2026-03-19
A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
GlaxoSmithKline
Phase 3 Not yet recruiting
NCT02502266 2026-03-05
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
NCT06619236 2026-03-03
RAINFOL-02
Genmab
Phase 3 Active not recruiting
NCT04697628 2026-02-24
innovaTV 301
Seagen Inc.
Phase 3 Completed